A5017265159- AI in cancer detection
- Chronic Lymphocytic Leukemia Research
- Cancer Genomics and Diagnostics
- Colorectal Cancer Screening and Detection
- Chronic Myeloid Leukemia Treatments
- PI3K/AKT/mTOR signaling in cancer
- Cancer Immunotherapy and Biomarkers
- Cell death mechanisms and regulation
- Veterinary Oncology Research
- Health and Medical Research Impacts
- Genetics, Aging, and Longevity in Model Organisms
- BRCA gene mutations in cancer
- Animal testing and alternatives
- Cancer, Stress, Anesthesia, and Immune Response
- Poxvirus research and outbreaks
- Advanced Electron Microscopy Techniques and Applications
- SARS-CoV-2 and COVID-19 Research
- Gene expression and cancer classification
- Breast Cancer Treatment Studies
- Breast Lesions and Carcinomas
- Cancer therapeutics and mechanisms
- Sirtuins and Resveratrol in Medicine
- Bacillus and Francisella bacterial research
- Medicinal Plants and Bioactive Compounds
- Science, Research, and Medicine
Harvard University
2010-2023
Brigham and Women's Hospital
2018-2023
Beth Israel Deaconess Medical Center
2010-2020
Cancer Research Institute
2017
Carol Davila University of Medicine and Pharmacy
2013
Modified median and subgroup-specific gene centering are two essential preprocessing methods to assign breast cancer molecular subtypes by PAM50. We evaluated the PAM50 derived from both in a subset of Nurses' Health Study (NHS) NHSII participants; correlated tumor with IHC surrogates; characterized subtype distribution, proliferation scores, risk relapse size weighted (ROR-PT) scores NHS/NHSII.
Emergence of resistance to Tyrosine-Kinase Inhibitors (TKIs), such as imatinib, dasatinib and nilotinib, in Chronic Myelogenous Leukemia (CML) demands new therapeutic strategies. We others have previously established bortezomib, a selective proteasome inhibitor, an important potential treatment CML. Here we show that the combined regimens bortezomib with mitotic inhibitors, microtubule-stabilizing agent Paclitaxel PLK1 inhibitor BI2536, efficiently kill TKIs-resistant -sensitive...
New biomarkers of risk may improve breast cancer (BC) prediction. We developed a computational pathology method to segment benign disease (BBD) whole slide images into epithelium, fibrous stroma, and fat. applied our the BBD BC nested case-control study within Nurses' Health Studies assess whether computer-derived tissue composition or morphometric signature was associated with subsequent BC.
Leukemia and lymphoma are systemic malignancies that represent half of all childhood cancers, though 90% occur in adults. Various treatment options available, but therapy is mainly chemotherapy plus appropriate monoclonal antibodies. In certain situations radiotherapy bone marrow transplantation play a role. Some types/subtypes these diseases potentially curable, yet many leukemias lymphomas do not properly respond to current therapies. Although the FDA (US Food Drugs Administration)...
Abstract Background New biomarkers of risk may improve breast cancer prediction. We developed a computational pathology method to segment benign disease (BBD) whole slide images (WSIs) into epithelium, fibrous stroma, and fat. applied our the BBD nested case-control study within Nurses’ Health Studies assess whether computer-derived tissue composition or morphometric signature was associated with subsequent cancer. Methods Tissue segmentation nuclei detection deep-learning networks were...
Genomic instability, as measured by chromosomal copy number alterations (CNAs), is associated with progression of ductal carcinoma in situ (DCIS) to invasive breast (IBC), and is, therefore, a potential prognostic marker. In this work, we develop novel image analysis pipeline that utilizes cascade biologically salient deep learning models identify malignant epithelial cells quantify CNAs. Our automatic approach measures CNAs high degree agreement those observed human examiners performs...
Abstract Bcr-Abl fusion protein plays a critical role in the pathogenesis and progression of Chronic Myelogenous Leukemia (CML) some Acute Lymphocytic (ALL) cases. Current inhibitors Abl kinases, such as Imatinib, have shown great promise treatment CML, however, emergence resistance persistence residual disease underlined importance finding new ways CML especially resistant forms CML. We others previously that Bortezomib (FDA approved for Multiple Myeloma), selective proteasome inhibitor,...